{"id":"oxitropium","rwe":[{"pmid":"40076331","year":"2025","title":"Structural Evolution Leading to the Thermosalient Phase Transition of Oxitropium Bromide.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"38109505","year":"2024","title":"Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease.","finding":"","journal":"Journal of AOAC International","studyType":"Clinical Study"},{"pmid":"35752979","year":"2022","title":"Muscarinic Receptor Antagonism and Allergen Induced Airway Responses in Allergic Asthma: A Scoping Review.","finding":"","journal":"Clinical and investigative medicine. Medecine clinique et experimentale","studyType":"Clinical Study"},{"pmid":"32058292","year":"2020","title":"Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"31254549","year":"2019","title":"Identification of metabolites identical and similar to drugs as candidates for metabolic engineering.","finding":"","journal":"Journal of biotechnology","studyType":"Clinical Study"}],"tags":[{"label":"oxitropium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"R03BB02","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic obstructive lung disease","category":"indication"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oxytropium bromide","offLabel":[],"synonyms":["oxitropium iodide","oxytropium bromide","oxitropium","oxitropium bromide"],"timeline":[],"aiSummary":"Oxytropium bromide is a small molecule medication used to treat conditions such as chronic obstructive pulmonary disease (COPD) and critical illness. It is administered via a metered dose inhaler, powder inhalation capsules, or other formulations like Ventilat, Tiotropium, and Tersigan.","approvals":[],"brandName":"Oxytropium Bromide","ecosystem":[{"indication":"Chronic obstructive lung disease","otherDrugs":[{"name":"aclidinium bromide","slug":"aclidinium-bromide","company":"Astrazeneca Pharms"},{"name":"arformoterol","slug":"arformoterol","company":"Sunovion"},{"name":"fluticasone furoate","slug":"fluticasone-furoate","company":"Glaxosmithkline"},{"name":"glycopyrronium bromide","slug":"glycopyrronium-bromide","company":"Shionogi Inc"}],"globalPrevalence":391900000}],"mechanism":{"modality":"Small Molecule","drugClass":"oxitropium","explanation":"Imagine your airways are like a narrow tube. When you breathe, the muscles around the tube relax, allowing air to flow in and out. Oxytropium helps keep these muscles relaxed, making it easier to breathe by blocking the signal that tells them to contract.","oneSentence":"Oxytropium works by blocking the action of acetylcholine, a neurotransmitter that causes airway muscles to contract.","technicalDetail":"Oxytropium is a muscarinic receptor antagonist that selectively blocks the M3 receptor subtype, preventing acetylcholine from binding and causing airway smooth muscle contraction."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2022","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OXITROPIUM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXITROPIUM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:10:26.061328","biosimilars":[],"competitors":[{"drugName":"ipratropium","drugSlug":"ipratropium","fdaApproval":"1986-12-29","patentExpiry":"Jan 17, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tiotropium bromide","drugSlug":"tiotropium-bromide","fdaApproval":"2004-01-30","patentExpiry":"Sep 30, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aclidinium bromide","drugSlug":"aclidinium-bromide","fdaApproval":"2012-07-23","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"glycopyrronium bromide","drugSlug":"glycopyrronium-bromide","fdaApproval":"1961-08-11","relationship":"same-class"},{"drugName":"umeclidinium","drugSlug":"umeclidinium","fdaApproval":"2013-12-18","patentExpiry":"Dec 18, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"revefenacin","drugSlug":"revefenacin","fdaApproval":"2018-11-09","patentExpiry":"Oct 31, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"oxitropium","indications":{"approved":[{"name":"Chronic obstructive lung disease","source":"DrugCentral","snomedId":13645005,"regulator":"FDA","usPrevalence":null,"globalPrevalence":391900000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Respir Med, 2019 (PMID:35279265)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ipratropium","brandName":"ipratropium","genericName":"ipratropium","approvalYear":"1986","relationship":"same-class"},{"drugId":"tiotropium-bromide","brandName":"tiotropium bromide","genericName":"tiotropium bromide","approvalYear":"2004","relationship":"same-class"},{"drugId":"aclidinium-bromide","brandName":"aclidinium bromide","genericName":"aclidinium bromide","approvalYear":"2012","relationship":"same-class"},{"drugId":"glycopyrronium-bromide","brandName":"glycopyrronium bromide","genericName":"glycopyrronium bromide","approvalYear":"1961","relationship":"same-class"},{"drugId":"umeclidinium","brandName":"umeclidinium","genericName":"umeclidinium","approvalYear":"2013","relationship":"same-class"},{"drugId":"revefenacin","brandName":"revefenacin","genericName":"revefenacin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02509299","phase":"NA","title":"Effect of Physiotherapy in Hospitalized COPD Patients","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2019-09-01","conditions":["COPD"],"enrollment":49,"completionDate":"2019-12-14"},{"nctId":"NCT03060018","phase":"NA","title":"Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values","status":"COMPLETED","sponsor":"Vera Bernet, MD","startDate":"2017-08-17","conditions":["Critical Illness"],"enrollment":113,"completionDate":"2018-12-31"},{"nctId":"NCT02172430","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-09","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":161,"completionDate":""},{"nctId":"NCT02515318","phase":"NA","title":"Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":["COPD"],"enrollment":60,"completionDate":"2018-07"},{"nctId":"NCT02238184","phase":"","title":"Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":105,"completionDate":""},{"nctId":"NCT02233920","phase":"","title":"Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":716,"completionDate":""},{"nctId":"NCT02233907","phase":"","title":"Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":595,"completionDate":""},{"nctId":"NCT02172807","phase":"PHASE3","title":"Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-12","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":201,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004014","UNII":"8G15T83E6I","CHEBI":"CHEBI:135418","INN_ID":"3955","RXNORM":"32649","UMLSCUI":"C0069776","ChEMBL_ID":"CHEMBL4297364","KEGG_DRUG":"D01946","DRUGBANK_ID":"DB12086","PUBCHEM_CID":"6917866","SNOMEDCT_US":"349953003","SECONDARY_CAS_RN":"30286-75-0","MESH_SUPPLEMENTAL_RECORD_UI":"C017590"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"1%"},"publicationCount":135,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"R03BB02","allCodes":["R03BB02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Feb 28","pmid":"40076331","title":"Structural Evolution Leading to the Thermosalient Phase Transition of Oxitropium Bromide.","journal":"Molecules (Basel, Switzerland)"},{"date":"2024 Mar 1","pmid":"38109505","title":"Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease.","journal":"Journal of AOAC International"},{"date":"2022 Jun 26","pmid":"35752979","title":"Muscarinic Receptor Antagonism and Allergen Induced Airway Responses in Allergic Asthma: A Scoping Review.","journal":"Clinical and investigative medicine. Medecine clinique et experimentale"},{"date":"2020 May 10","pmid":"32058292","title":"Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2019 Aug 20","pmid":"31254549","title":"Identification of metabolites identical and similar to drugs as candidates for metabolic engineering.","journal":"Journal of biotechnology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}